115 related articles for article (PubMed ID: 31556440)
1. Neurotransmitter selection by monoamine oxidase isoforms, dissected in terms of functional groups by mixed double mutant cycles.
Hudspith L; Shmam F; Dalton CF; Princivalle A; Turega SM
Org Biomol Chem; 2019 Oct; 17(39):8871-8877. PubMed ID: 31556440
[TBL] [Abstract][Full Text] [Related]
2. Phenethylamine is a substrate of monoamine oxidase B in the paraventricular thalamic nucleus.
Obata Y; Kubota-Sakashita M; Kasahara T; Mizuno M; Nemoto T; Kato T
Sci Rep; 2022 Jan; 12(1):17. PubMed ID: 34996979
[TBL] [Abstract][Full Text] [Related]
3. Is one amino acid responsible for substrate specificity of monoamine oxidase A and B?
Veselovsky AV; Ivanov AS; Medvedev AE
Biochemistry (Mosc); 1998 Dec; 63(12):1441-6. PubMed ID: 9916164
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relations in the oxidation of phenethylamine analogues by recombinant human liver monoamine oxidase A.
Nandigama RK; Edmondson DE
Biochemistry; 2000 Dec; 39(49):15258-65. PubMed ID: 11106506
[TBL] [Abstract][Full Text] [Related]
5. Expression of functional human monoamine oxidase A and B cDNAs in mammalian cells.
Lan NC; Chen CH; Shih JC
J Neurochem; 1989 May; 52(5):1652-4. PubMed ID: 2496202
[TBL] [Abstract][Full Text] [Related]
6. Profiling substrate specificity of two series of phenethylamine analogs at monoamine oxidase A and B.
Heuson E; Storgaard M; Huynh TH; Charmantray F; Gefflaut T; Bunch L
Org Biomol Chem; 2014 Nov; 12(43):8689-95. PubMed ID: 25253656
[TBL] [Abstract][Full Text] [Related]
7. Loss of serotonin oxidation as a component of the altered substrate specificity in the Y444F mutant of recombinant human liver MAO A.
Nandigama RK; Miller JR; Edmondson DE
Biochemistry; 2001 Dec; 40(49):14839-46. PubMed ID: 11732903
[TBL] [Abstract][Full Text] [Related]
8. Insight into the functional and structural properties of 3-arylcoumarin as an interesting scaffold in monoamine oxidase B inhibition.
Matos MJ; Vilar S; García-Morales V; Tatonetti NP; Uriarte E; Santana L; Viña D
ChemMedChem; 2014 Jul; 9(7):1488-500. PubMed ID: 24715707
[TBL] [Abstract][Full Text] [Related]
9. Why does the Y326I mutant of monoamine oxidase B decompose an endogenous amphetamine at a slower rate than the wild type enzyme? Reaction step elucidated by multiscale molecular simulations.
Pregeljc D; Jug U; Mavri J; Stare J
Phys Chem Chem Phys; 2018 Feb; 20(6):4181-4188. PubMed ID: 29360121
[TBL] [Abstract][Full Text] [Related]
10. Characterization of monoamine oxidase isoforms in human islets of Langerhans.
Pizzinat N; Chan SL; Remaury A; Morgan NG; Parini A
Life Sci; 1999; 65(4):441-8. PubMed ID: 10421430
[TBL] [Abstract][Full Text] [Related]
11. [Mechanistic study of monoamine oxidase: significance for MAO A and MAO B in situ].
Ramsay RR
Vopr Med Khim; 1997; 43(6):457-70. PubMed ID: 9503563
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor design for monoamine oxidases.
Ramsay RR
Curr Pharm Des; 2013; 19(14):2529-39. PubMed ID: 23116392
[TBL] [Abstract][Full Text] [Related]
13. Investigation on the structure of the active site of monoamine oxidase-B by affinity labeling with the selective inhibitor lazabemide and by site-directed mutagenesis.
Cesura AM; Gottowik J; Lahm HW; Lang G; Imhof R; Malherbe P; Röthlisberger U; Da Prada M
Eur J Biochem; 1996 Mar; 236(3):996-1002. PubMed ID: 8665924
[TBL] [Abstract][Full Text] [Related]
14. On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B.
McDonald GR; Olivieri A; Ramsay RR; Holt A
Pharmacol Res; 2010 Dec; 62(6):475-88. PubMed ID: 20832472
[TBL] [Abstract][Full Text] [Related]
15. A Perspective on Monoamine Oxidase Enzyme as Drug Target: Challenges and Opportunities.
Kumar B; Gupta VP; Kumar V
Curr Drug Targets; 2017; 18(1):87-97. PubMed ID: 26648064
[TBL] [Abstract][Full Text] [Related]
16. New Frontiers in Selective Human MAO-B Inhibitors.
Carradori S; Silvestri R
J Med Chem; 2015 Sep; 58(17):6717-32. PubMed ID: 25915162
[TBL] [Abstract][Full Text] [Related]
17. Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases.
Wagmann L; Brandt SD; Stratford A; Maurer HH; Meyer MR
Drug Test Anal; 2019 Feb; 11(2):318-324. PubMed ID: 30188017
[TBL] [Abstract][Full Text] [Related]
18. Variations in activity and inhibition with pH: the protonated amine is the substrate for monoamine oxidase, but uncharged inhibitors bind better.
Jones TZ; Balsa D; Unzeta M; Ramsay RR
J Neural Transm (Vienna); 2007; 114(6):707-12. PubMed ID: 17401535
[TBL] [Abstract][Full Text] [Related]
19. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
Sterling J; Herzig Y; Goren T; Finkelstein N; Lerner D; Goldenberg W; Miskolczi I; Molnar S; Rantal F; Tamas T; Toth G; Zagyva A; Zekany A; Finberg J; Lavian G; Gross A; Friedman R; Razin M; Huang W; Krais B; Chorev M; Youdim MB; Weinstock M
J Med Chem; 2002 Nov; 45(24):5260-79. PubMed ID: 12431053
[TBL] [Abstract][Full Text] [Related]
20. A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors.
Mattsson C; Svensson P; Sonesson C
Eur J Med Chem; 2014 Feb; 73():177-86. PubMed ID: 24393810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
